The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Covid-19 in pharma: synthetic COVID vaccines. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Synthetic COVID vaccines is a key innovation area in Covid-19 therapy
Synthetic COVID vaccines refer to vaccines that are designed and produced using synthetic biology techniques, rather than traditional methods of vaccine production. A synthetic vaccine mainly consists of synthetic peptides, carbohydrates, or antigens for COVID. They are usually considered to be safer than vaccines from bacterial cultures. Creating vaccines synthetically can increase the speed of production.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 960+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of synthetic COVID vaccines.
Key players in synthetic COVID vaccines – a disruptive innovation in the pharmaceutical industry
Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Johnson & Johnson (J&J) is one of the leading patent filers in synthetic COVID vaccines. J&J researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious such as Covid-19, cardiovascular, and metabolic diseases. Jcovden is an approved synthetic vaccine, which was developed by Johnson & Johnson. GSK and Sanofi are some of the other key patent filers in synthetic COVID vaccines.
In terms of application diversity, Revvity leads the pack, while Gilead Sciences and Bio-Rad Laboratories stood in the second and third positions, respectively.
By means of geographic reach, SEEK Group held the top position, followed by Autoimmune Technologies and TheVax Genetics Vaccine.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
